Suppr超能文献

药物与人肝微粒体的非特异性结合。

Nonspecific binding of drugs to human liver microsomes.

作者信息

McLure J A, Miners J O, Birkett D J

机构信息

Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University School of Medicine, Adelaide, Australia.

出版信息

Br J Clin Pharmacol. 2000 May;49(5):453-61. doi: 10.1046/j.1365-2125.2000.00193.x.

Abstract

AIMS

To characterize the nonspecific binding to human liver microsomes of drugs with varying physicochemical characteristics, and to develop a model for the effect of nonspecific binding on the in vitro kinetics of drug metabolism enzymes.

METHODS

The extent of nonspecific binding to human liver microsomes of the acidic drugs caffeine, naproxen, tolbutamide and phenytoin, and of the basic drugs amiodarone, amitriptyline and nortriptyline was investigated. These drugs were chosen for study on the basis of their lipophilicity, charge, and extent of ionization at pH 7.4. The fraction of drug unbound in the microsomal mixture, fu(mic), was determined by equilibrium dialysis against 0.1 M phosphate buffer, pH 7.4. The data were fitted to a standard saturable binding model defined by the binding affinity KD, and the maximum binding capacity Bmax. The derived binding parameters, KD and Bmax, were used to simulate the effects of saturable nonspecific binding on in vitro enzyme kinetics.

RESULTS

The acidic drugs caffeine, tolbutamide and naproxen did not bind appreciably to the microsomal membrane. Phenytoin, a lipophilic weak acid which is mainly unionized at pH 7. 4, was bound to a small extent (fu(mic) = 0.88) and the binding did not depend on drug concentration over the range used. The three weak bases amiodarone, amitriptyline and nortriptyline all bound extensively to the microsomal membrane. The binding was saturable for nortriptyline and amitriptyline. Bmax and KD values for nortriptyline at 1 mg ml-1 microsomal protein were 382 +/- 54 microM and 147 +/- 44 microM, respectively, and for amitriptyline were 375 +/- 23 microM and 178 +/- 33 microM, respectively. Bmax, but not KD, varied approximately proportionately with the microsome concentration. When KD is much less than the Km for a reaction, the apparent Km based on total drug can be corrected by multiplying by fu(mic). When the substrate concentration used in a kinetic study is similar to or greater than the KD (Km >/= KD), simulations predict complex effects on the reaction kinetics. When expressed in terms of total drug concentrations, sigmoidal reaction velocity vs substrate concentration plots and curved Eadie Hofstee plots are predicted.

CONCLUSIONS

Nonspecific drug binding in microsomal incubation mixtures can be qualitatively predicted from the physicochemical characteristics of the drug substrate. The binding of lipophilic weak bases is saturable and can be described by a standard binding model. If the substrate concentrations used for in vitro kinetic studies are in the saturable binding range, complex effects are predicted on the reaction kinetics when expressed in terms of total (added) drug concentration. Sigmoidal reaction curves result which are similar to the Hill plots seen with cooperative substrate binding.

摘要

目的

表征具有不同物理化学特性的药物与人肝微粒体的非特异性结合,并建立非特异性结合对药物代谢酶体外动力学影响的模型。

方法

研究了酸性药物咖啡因、萘普生、甲苯磺丁脲和苯妥英以及碱性药物胺碘酮、阿米替林和去甲替林与人肝微粒体的非特异性结合程度。选择这些药物进行研究是基于它们的亲脂性、电荷以及在pH 7.4时的电离程度。通过与0.1 M pH 7.4的磷酸盐缓冲液进行平衡透析来测定微粒体混合物中未结合药物的分数fu(mic)。将数据拟合到由结合亲和力KD和最大结合容量Bmax定义的标准可饱和结合模型。导出的结合参数KD和Bmax用于模拟可饱和非特异性结合对体外酶动力学的影响。

结果

酸性药物咖啡因、甲苯磺丁脲和萘普生与微粒体膜的结合不明显。苯妥英是一种亲脂性弱酸,在pH 7.4时主要以非离子形式存在,有少量结合(fu(mic)=0.88),且在所使用的浓度范围内结合不依赖于药物浓度。三种弱碱性药物胺碘酮、阿米替林和去甲替林都与微粒体膜广泛结合。去甲替林和阿米替林的结合是可饱和的。在1 mg/ml微粒体蛋白时,去甲替林的Bmax和KD值分别为382±54 μM和147±44 μM,阿米替林的分别为375±23 μM和178±33 μM。Bmax而非KD随微粒体浓度大致成比例变化。当KD远小于反应的Km时,基于总药物的表观Km可通过乘以fu(mic)进行校正。当动力学研究中使用的底物浓度与KD相似或大于KD(Km≥KD)时,模拟预测对反应动力学有复杂影响。当以总药物浓度表示时,预测会出现S形反应速度与底物浓度图和弯曲的伊迪 - 霍夫斯泰因图。

结论

微粒体孵育混合物中的非特异性药物结合可根据药物底物的物理化学特性进行定性预测。亲脂性弱碱的结合是可饱和的,可用标准结合模型描述。如果用于体外动力学研究的底物浓度处于可饱和结合范围内,当以总(添加)药物浓度表示时,预测对反应动力学会有复杂影响。会产生S形反应曲线,类似于底物协同结合时看到的希尔图。

相似文献

1
Nonspecific binding of drugs to human liver microsomes.
Br J Clin Pharmacol. 2000 May;49(5):453-61. doi: 10.1046/j.1365-2125.2000.00193.x.

引用本文的文献

2
Many human pharmaceuticals are weak inhibitors of the cytochrome P450 system in rainbow trout () liver S9 fractions.
Front Toxicol. 2024 Jul 15;6:1406942. doi: 10.3389/ftox.2024.1406942. eCollection 2024.
5
Analyte recovery in LC-MS/MS bioanalysis: An old issue revisited.
Anal Chim Acta. 2022 Mar 15;1198:339512. doi: 10.1016/j.aca.2022.339512. Epub 2022 Jan 28.
7
How Science Is Driving Regulatory Guidances.
Methods Mol Biol. 2021;2342:595-629. doi: 10.1007/978-1-0716-1554-6_19.
8
Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.
Pharmacol Ther. 2020 Feb;206:107449. doi: 10.1016/j.pharmthera.2019.107449. Epub 2019 Dec 11.
10
Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation.
Drug Metab Dispos. 2019 Jul;47(7):732-742. doi: 10.1124/dmd.118.085969. Epub 2019 May 1.

本文引用的文献

1
Protein measurement with the Folin phenol reagent.
J Biol Chem. 1951 Nov;193(1):265-75.
2
Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.
Br J Clin Pharmacol. 1999 Jun;47(6):625-35. doi: 10.1046/j.1365-2125.1999.00935.x.
4
Autoactivation and activation of the cytochrome P450s.
Int J Clin Pharmacol Ther. 1998 Dec;36(12):642-51.
5
Inhibition and induction of cytochrome P450 and the clinical implications.
Clin Pharmacokinet. 1998 Nov;35(5):361-90. doi: 10.2165/00003088-199835050-00003.
6
Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.
J Clin Pharmacol. 1998 Feb;38(2):112-21. doi: 10.1002/j.1552-4604.1998.tb04399.x.
10
Examination of purported probes of human CYP2B6.
Pharmacogenetics. 1997 Jun;7(3):165-79. doi: 10.1097/00008571-199706000-00001.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验